GLP-1 Drugs and Alzheimer's Research

Why scientists hoped diabetes and weight-loss drugs like semaglutide might slow Alzheimer's, what the big evoke trials found, and what it means for people taking these medicines.

Last reviewed: October 2026

Few medicines have made headlines like GLP-1 drugs—semaglutide (sold as Ozempic, Wegovy and Rybelsus), liraglutide, tirzepatide and others. Originally developed for type 2 diabetes, they are now widely used for weight loss. For several years, researchers have also wondered: could these drugs protect the brain against Alzheimer's disease?

In late 2025, the largest test of that idea delivered a clear answer for one drug and one stage of disease. Here's what happened and what it means.

What are GLP-1 drugs?

GLP-1 (glucagon-like peptide-1) is a natural hormone that helps control blood sugar and appetite. GLP-1 receptor agonists mimic that hormone. They lower blood sugar, help people feel full, and lead to weight loss. Some have also been shown to reduce heart attacks and strokes in certain high-risk people.

Why scientists were hopeful

Several lines of evidence suggested a possible brain benefit:

Diabetes and obesity are linked to dementia risk, so treating them well might help the brain—see Reducing Dementia Risk: The 14 Risk Factors.
Lab and animal studies suggested GLP-1 drugs might reduce brain inflammation and protect nerve cells.
Real-world data from health records hinted that people taking GLP-1 drugs had lower rates of dementia diagnoses.
Re-analyses of diabetes and obesity trials suggested fewer dementia cases among people on these drugs.

But observational data can be misleading: people who get prescribed new medicines may differ in many ways from people who don't. The only way to know is a large randomized trial. (See how to read health research news.)

The evoke and evoke+ trials

Novo Nordisk, the maker of semaglutide, ran two large Phase 3 trials called evoke and evoke+. According to the Alzheimer's Association and the published results in The Lancet:

They enrolled 3,808 people ages 55 to 85 at hundreds of sites in 40 countries.
Participants had mild cognitive impairment or mild dementia due to Alzheimer's, with amyloid confirmed by PET scan or spinal fluid testing.
They took oral semaglutide (up to 14 mg daily) or a placebo pill, on top of their usual care, for two years (with a planned extension).
The main measure was the Clinical Dementia Rating–Sum of Boxes (CDR-SB), a standard score of thinking and daily function.

What they found

On November 24, 2025, the company announced that semaglutide did not slow Alzheimer's progression compared with placebo. Full results were presented at the CTAD conference in December 2025 and later published in The Lancet:

After two years, scores worsened by almost exactly the same amount in both groups—in evoke, an average of 2.3 points with semaglutide and 2.3 with placebo; in evoke+, 2.2 versus 2.1.
Secondary measures of thinking and function also showed no meaningful benefit, according to Alzheimer Europe.
Semaglutide did improve some Alzheimer's-related biomarkers in blood and spinal fluid, but this did not translate into slower decline.
Side effects matched what's known for semaglutide, mainly gastrointestinal symptoms and weight loss.
Both trials, including their planned extension phase, were discontinued because of the negative results.

The Alzheimer's Association said it was disappointed but emphasized that every trial, regardless of outcome, helps "inform the next generation of clinical trials." Its chief science officer noted that the field will keep studying this class of drugs, because different GLP-1 medicines may act differently.

What this means

For people with early Alzheimer's: Oral semaglutide is not a treatment for Alzheimer's disease. Approved options for early Alzheimer's include anti-amyloid drugs such as Lecanemab (Leqembi) and Donanemab (Kisunla), plus symptomatic treatments—see Dementia Treatments: An Overview. Talk with your doctor about what fits.

For people already taking a GLP-1 drug: These results don't change why you take it. GLP-1 drugs can be very effective for diabetes and weight, and controlling those conditions is good for overall and heart health. Don't start, stop or change any medicine without talking to your doctor.

For prevention: The evoke trials tested people who already had symptoms. Whether GLP-1 drugs could help prevent dementia in people at risk—or whether other GLP-1 drugs or injectable forms work differently—remains an open research question. For now, the proven steps for brain health are lifestyle and risk-factor control—see Reducing Dementia Risk: The 14 Risk Factors.

For research: Large, well-run negative trials are valuable. They prevent years of false hope and redirect money and volunteers toward more promising ideas. The Alzheimer's drug pipeline remains busy, with the Alzheimer's Association citing 182 active trials testing 138 drugs in early 2025.

A lesson about headlines

The GLP-1 story is a reminder that promising signals from animal studies and health-record analyses don't always hold up. Be cautious about headlines claiming a common medicine "prevents Alzheimer's." Look for results from randomized controlled trials in people.

How to get involved

If you or a loved one is interested in testing new treatments, ask your doctor about research opportunities or visit the Alzheimer's Association's TrialMatch or ClinicalTrials.gov. See Joining a Clinical Trial.

Bottom line

The large evoke and evoke+ trials found that oral semaglutide did not slow early Alzheimer's disease, despite earlier hopes. GLP-1 drugs remain important for diabetes and weight management, and research on the brain continues. Talk with your doctor before making any medication decisions.

Sources

Not medical advice. This article is general information, not a diagnosis or treatment plan for any individual. Talk with a doctor about your situation.

Ask a question

Have a question about memory, Alzheimer's, or caregiving? Email us at:

[email protected]

Open in my email app · Write in Gmail (opens in a new tab)

We may answer common questions in future updates (we won't share your name). We can't give personal medical advice; for urgent help call the Alzheimer's Association Helpline at 800-272-3900.

Memory Digest